JP2022500433A5 - - Google Patents

Info

Publication number
JP2022500433A5
JP2022500433A5 JP2021514073A JP2021514073A JP2022500433A5 JP 2022500433 A5 JP2022500433 A5 JP 2022500433A5 JP 2021514073 A JP2021514073 A JP 2021514073A JP 2021514073 A JP2021514073 A JP 2021514073A JP 2022500433 A5 JP2022500433 A5 JP 2022500433A5
Authority
JP
Japan
Prior art keywords
cancer
compound
solid form
pharmaceutical composition
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500433A (ja
JP7731794B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001011 external-priority patent/WO2020053657A1/en
Publication of JP2022500433A publication Critical patent/JP2022500433A/ja
Publication of JP2022500433A5 publication Critical patent/JP2022500433A5/ja
Priority to JP2025137091A priority Critical patent/JP2025179092A/ja
Application granted granted Critical
Publication of JP7731794B2 publication Critical patent/JP7731794B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514073A 2018-09-13 2019-09-13 Betブロモドメイン阻害剤の固体形態の製造方法 Active JP7731794B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025137091A JP2025179092A (ja) 2018-09-13 2025-08-20 Betブロモドメイン阻害剤の固体形態の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730849P 2018-09-13 2018-09-13
US62/730,849 2018-09-13
PCT/IB2019/001011 WO2020053657A1 (en) 2018-09-13 2019-09-13 Method of manufacturing a solid form of a bet bromodomain inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025137091A Division JP2025179092A (ja) 2018-09-13 2025-08-20 Betブロモドメイン阻害剤の固体形態の製造方法

Publications (3)

Publication Number Publication Date
JP2022500433A JP2022500433A (ja) 2022-01-04
JP2022500433A5 true JP2022500433A5 (cg-RX-API-DMAC7.html) 2022-09-20
JP7731794B2 JP7731794B2 (ja) 2025-09-01

Family

ID=69777480

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514073A Active JP7731794B2 (ja) 2018-09-13 2019-09-13 Betブロモドメイン阻害剤の固体形態の製造方法
JP2025137091A Pending JP2025179092A (ja) 2018-09-13 2025-08-20 Betブロモドメイン阻害剤の固体形態の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025137091A Pending JP2025179092A (ja) 2018-09-13 2025-08-20 Betブロモドメイン阻害剤の固体形態の製造方法

Country Status (14)

Country Link
US (2) US12145932B2 (cg-RX-API-DMAC7.html)
EP (2) EP3849980B1 (cg-RX-API-DMAC7.html)
JP (2) JP7731794B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210080373A (cg-RX-API-DMAC7.html)
CN (1) CN112955449B (cg-RX-API-DMAC7.html)
AU (1) AU2019338059B2 (cg-RX-API-DMAC7.html)
CA (1) CA3111527A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190598A1 (cg-RX-API-DMAC7.html)
ES (1) ES3034982T3 (cg-RX-API-DMAC7.html)
IL (1) IL281258B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002885A (cg-RX-API-DMAC7.html)
SG (1) SG11202102497SA (cg-RX-API-DMAC7.html)
TW (1) TWI882964B (cg-RX-API-DMAC7.html)
WO (1) WO2020053657A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法
TW202327594A (zh) 2021-09-23 2023-07-16 大陸商恒翼生物醫藥(上海)股份有限公司 用bet溴結構域抑制劑和parp抑制劑的組合治療預選患者群體的三陰性乳腺癌的方法
KR102619331B1 (ko) * 2021-11-30 2023-12-29 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN105473581B (zh) 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
KR102307566B1 (ko) * 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
CA2966452A1 (en) 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
WO2017075377A1 (en) * 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN109715625B (zh) * 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
TWI816880B (zh) 2018-09-13 2023-10-01 大陸商恒翼生物醫藥(上海)股份有限公司 治療前列腺癌之組合療法
TWI841598B (zh) 2018-09-13 2024-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 用於治療雌激素受體陽性乳癌之組合療法
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法

Similar Documents

Publication Publication Date Title
TWI576343B (zh) 5-氯-n2-(2-異丙氧基-5-甲基-4-六氫吡啶-4-基-苯基)-n4-[2-(丙烷-2-磺醯基)-苯基]-嘧啶-2,4-二胺之結晶型式
TWI697495B (zh) 科帕利普(copanlisib)及其二鹽酸鹽之合成
CN104024262B (zh) 埃克替尼和盐酸埃克替尼的制备方法及其中间体
US20250034142A1 (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
CN103570633B (zh) 吉非替尼的制备方法
TW201625633A (zh) 科帕利普(copanlisib)及其二鹽酸鹽之合成
CN105517992A (zh) 新型结晶性芳烷基胺化合物及其制造方法
CN104151359A (zh) 喹唑啉类化合物及其制备方法和在制备酪氨酸激酶抑制剂中的应用
CN112279838B (zh) 一种吡咯替尼的制备方法
BR112021005274A2 (pt) métodos para produção de compostos de pirazol
JP6594333B2 (ja) Hx塩の形態の(e)−4−n,n−ジアルキルアミノクロトン酸の製造方法、およびegfrチロシンキナーゼ阻害剤の合成のためのその使用
WO2019037591A1 (zh) 盐酸美法仑晶型及其制备方法与应用
CN108329236B (zh) 一种恩杂鲁胺中间体的制备方法
JP2015038053A (ja) 4−(2−メチル−1−イミダゾリル)−2,2−フェニルブタンアミドの製造方法
WO2022135300A1 (zh) 1-苄基-4-甲基-5-烷氧基-1,2,3,6-四氢吡啶衍生物的合成及应用
JP2022552329A5 (cg-RX-API-DMAC7.html)
CN119552161B (zh) 图卡替尼中间体4-([1,2,4]三唑并[1,5-a]吡啶-7-氧基)-3-甲基苯胺的制备工艺
CN111499622A (zh) 一种治疗胆管癌的药物的制备方法
HK40053356B (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
CN115785081A (zh) 一种雷替曲塞的制备方法
HK40053356A (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
EP1907379A1 (en) Crystalline forms of (2r-trans)-6-chloro-5ýý4-ý(4-fluorophenyl)methyl¨-2,5-dimethyl-1-piperazinyl¨carbonyl¨-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
TW200948783A (en) Process for producing compound having NPYY5 receptor antagonism and useful crystals